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The combination of low or moderate doses of inhaled corticosteroids (ICS) with long-
acting β2-agonists (LABA) improves asthma control in adults and reduces exacerbations.
1,2
The combination of ICS plus LABA for maintenance therapy has been endorsed in
guidelines for the treatment of moderate to severe asthma.
3 Recent pharmacogenetic
studies demonstrated that the β2-adrenergic receptor (ADRB2) polymorphism modifies
bronchodilating response to regular use of short-acting
4,5 and long-acting
6-8 β2-agonists.
Individuals homozygous for glycine (Gly) at codon 16 of the ADRB2 gene have greater
bronchodilation, measured as the forced expiratory volume in 1 second (FEV1) and
maximal mid-expiratory flow (MMEF) to regular treatment of albuterol
4,5 and salmeterol.
6,8
By contrast, a recent finding in a Korean population
9 showed that asthmatic patients with
the homozygous Arg/Arg genotype had a significantly greater response of acute
brochodilation to a short-acting β2-agonist. Some studies reported that ADRB2 genetic
polymorphisms did not result in significant change of bronchodilating response to short
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Purpose: Combination treatment of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) is widely used as a
maintenance regimen for the management of asthma. This study evaluated the effect of the β2-adrenergic receptor (ADRB2)
polymorphism on lung function and asthma control with regular use of combination treatment of an inhaled ICS plus
LABA. Materials and Methods: 43 Korean asthmatics who were symptomatic despite regular ICS use for at least 3
months were enrolled. For a 2-week run-in period, they received ICS (budesonide 800 µg/day) plus terbutaline (5 µg prn). as
needed. During the 24-week active treatment period, they received budesonide 160 µg and formoterol 4.5 µg b.i.d. as
maintenance and rescue medication. Pulmonary function and quality of life scores were monitored every 8 weeks;
morning/evening peak expiratory flow meter (PEFR) was recorded daily. Patients were genotyped for ADRB2 Arg16Gly
using single base extension methodology. Results: During the run-in period, there were no significant between-group
differences in lung function; after 8 weeks of active treatment, Arg/Arg patients had significantly higher forced expiratory
volume in 1 secord (FEV1) and maximal mid-expiratory flow (MMEF) (p = 0.023 and p = 0.021, respectively), and better
asthma control and quality of life after 24 weeks (p = 0.016 and p = 0.028, respectively). During treatment, there was a
greater improvement in morning/evening PEFR in Arg/Arg patients. Conclusion: Asthmatic patients with the Arg/Arg
genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and
formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy.
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10,11 and LABA,
12-14 and that other ethnic-
specific pharmacogenetic differences have been demonstrated
in individuals with different ADRB2 genotypes.
15 Therefore, to
elucidate whether there is a genotype-dependent influence or
any pharmaco-ethnic differences on the effects of regular use of
LABA combined with ICS in Korean asthmatics, we conducted
a 24-week trial of combined budesonide 160 µg and formoterol
4.5 µg in moderate asthmatics and compared clinical outcomes
according to the ADRB2 genotype.
Subjects and study design
This study was a long-term trial consisting of a 2-week run-in
and a 24-week active treatment period. Patients with modera-
tely persistent asthma were recruited, based on the Global
Initiative for Asthma (GINA) guidelines. All subjects partici-
pated in this study were ethnically Korean. Men and women,
aged 18-55 years with a documented history of asthma for at
least 6 months, no history of smoking or reported history of
viral infection in the proceeding 6 weeks, and an FEV1 of at
least 60% of the predicted value, were recruited at Ajou
University Hospital, Suwon, and Dankook University Hospital,
Cheonan, Korea. All study patients had not been exposed to
long acting β2 agonist for 3 months prior to this study, and they
provided written informed consent as approved by the local
committee on human research.
Outpatients included were required to have been on main-
tenance therapy with less than 800 µg of inhaled budesonide for
at least 3 months and to have a history of at least 1 asthma
exacerbation in the previous 12 months. For at least 30 days
before enrollment and during the 2-week run-in period, patients
took a constant daily dose of 800 µg of budesonide. To be
eligible, patients had to have an FEV1 of 60-100% of the
predicted value with 12% or more reversibility after 100 µg of
salbutamol inhalation compared to baseline, and should have
used a short-acting β2-agonist for asthma symptoms on at least
5 of the last 7 days of the run-in. During the 24-week active
treatment period, all patients were asked to use combination
therapy, while consisted of budesonide 160 µg and formoterol
4.5 µg combined in a device, twice a day as maintenance
treatment and for relief as needed. The pretreatment peak
expiratory flow meter (PEFR) was assessed twice daily using a
Mini-Wright PEFR meter (Clement Clark, Harlow, UK). Daily
symptoms, nocturnal awakenings, and rescue medication use
were recorded on diary cards. FEV1 was assessed 5 times (at -2,
0, 8, 16, and 24 weeks) by calibrated spirometry. Both PEFR
and FEV1 were presented as percent predicted values. An
Asthma Control Questionnaire (ACQ; range: 0, absent, to 6,
severe) was completed 4 times (at 0, 8, 16, and 24 weeks), and
the Asthma Quality of Life Questionnaire (AQLQ; range: 1,
severe impairment, to 7, not impaired) validated by the Korean
Society of Allergology
16 was recorded 3 times (at 0, 8, and 24
weeks).
Genotyping
Genotyping of the ADRB2 Arg16Gly polymorphism was
performed all study using a single base extension method. The
sequences of the amplifying and extension primers for the
ADRB2 Arg16Gly polymorphism were forward 5’AAAATTA
TGCTCCAGGAGTCTCA-3’, reverse 5’-ATAAGTTTCTTGG
CTGATTAAGATCA-3’, and extension 5’-tttacttgtgatgaatagaa
aaatt3’. Primer extension reactions were performed with the
SNaPshot ddNTP primer extension kit (Applied Biosystems,
Foster City, CA, USA). The results were analysed after
completion of this study, using the ABI Prism GeneScan and
Genotyper software (Applied Biosystems). Among the study
subjects, 13 individuals were Arg/Arg homozygous, 25
individuals were Arg/Gly heterozygous and 5 individuals were
Gly/Gly homozygous genotypes. Study subjects were catego-
rized into 2 groups: Arg/Arg and Arg/Gly plus Gly/Gly groups,
because of limited number for analysis.
Statistical analysis
Lung function [percent predicted value of FEV1, forced vital
capacity (FVC), and MMEF] and the change in ACQ and
AQLQ scores between groups were compared using the Mann-
Whitney U test. Student’s t-test was used to compare demogra-
phic data among the study groups. Values of p ≤ 0.05 were
regarded as significant. The primary outcome of the study was
asthma control characterized by FEV1 and MMEF (% predicted
value), measured at every visit. Secondary outcomes were
morning/evening PEFR (% predicted value), morning/evening
PEFR variability (evening PEFR minus morning PEFR as a
percentage of evening PEFR), asthma symptoms (range: 0
absent to 3 severe), frequency of rescue medication use, and
ACQ and AQLQ scores. Patients were stratified into two groups
depending on the ADRB2 codon 16 genotype, Arg/Arg and
Arg/Gly or Gly/Gly. Owing to the repeated measurements of
primary and secondary response variables within each phase of
experiment, longitudinal data analysis was applied within the
context of the intention-to-treat principle. Mean PEFR from
each individual was parallel transformed into origin of y axis at
starting point of the study. The transformed data were presented
as reversible PEFR. The data were fitted and modeled using a
non-linear regression (SIGMAPLOT 9.0) for the 2 genotype
groups. The regression equations were satisfied by indepen-
dency, normality and constant variance of residual error.
The clinical and physical characteristics of 43 enrolled patients
are shown in Table 1. There were no significant differences in
baseline spirometry results between the 2 genotype groups,
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MATERIALS AND METHODS
RESULTSwith the Arg/Arg genotype group having a mean FEV1 of
77.8% and the Arg/Gly or Gly/Gly genotype group having a
mean FEV1 of 73.5%. Mean age and serum total immuno
globulin (Ig) E level were significantly higher in the Arg/Gly or
Gly/Gly genotype group than in the Arg/Arg genotype group
(41.5 ± 10.9 vs. 30.8  ± 10.6 years, 2.34 ± 0.5 vs. 1.89 ± 0.57
IU/mL, p < 0.05, respectively). However, there were no signifi-
cant differences in gender, atopy rate, PC20 methacholine,
asthma duration, family history of asthma and frequency of
exacerbation according to the genotype (all  p> 0.05).
During the 2-week run-in period, both groups exhibited
increase of lung function, but no significant differences were
noted between the 2 groups. There was a significant increase of
FEV1 during the regularly scheduled combined treatment (p <
0.05) (Fig. 1). After 8 weeks of active treatment, treatment effects
differed significantly between the genotype groups: patients
with an Arg/Arg genotype had significantly higher FEV1% and
MMEF% than those with an Arg/Gly or Gly/Gly genotype (p <
0.05), whereas no significant differences between the groups
were noted for FVC%. This improvement appeared to persist
through subsequent 16 weeks, and the mean FEV1 and PEFR
levels were then decreased, with statistical significance lost by
Seung-Hyun Kim, et al.
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Table 1.Comparison of Clinical Characteristics of Study Subjects  Stratified by ADRB2 Genotype Group
Genotype
Arg/Arg Arg/Gly or Gly/Gly pvalue
(n = 13) (n = 30)
Age (yrs)* 30.8 ± 10.6 41.5 ± 10.9 0.005
Gender (M / F) 5 / 8 21 / 9 0.089 
Atopy (+ / -) 5 / 8 11 / 19 1.000 
Log total IgE (IU / mL)* 1.89 ± 0.57 2.34 ± 0.5 0.021
Baseline FEV1(%)* 77.8 ± 13.6 73.5 ± 12.1 0.316 
Asthma duration (yr)* 9.0 ± 6.5 6.2 ± 3.5 0.234 
Family history of asthma 4 / 9 7 / 23 0.709 
PC20 methacholine (mg / mL)* 6.75 ± 2.5 5.10 ± 2.4 0.646
Number of exacerbation (time / yr)* 0.50 ± 0.17 0.62 ± 0.1 0.602
FVC (% predicted) 80.5 ± 2.9 82.3 ± 2.6 0.698
MMEF (% predicted) 67.2 ± 7.9 52.4 ± 4.7 0.104
Morning PEFR (% predicted) 88.8 ± 6.3 83.8 ± 5.0 0.550
Evening PEFR (% predicted) 90.7 ± 6.4 89.3 ± 7.7 0.900
FEV1 increase after BDT (%)* 19.7 ± 2.3 19.9 ± 1.0 0.930
ADRB2, β2-adrenergic receptor; M, male; F, female; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; PEFR, peak 
expiratory flow rate; FEV1, forced expiratory volume in 1sec; BDT, bronchodilating test. 
*mean ± SD.
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Fig. 1. Mean (SD) % predicted value of FEV1 (A), FVC (B) and MMEF (C) during the study period (-2-0 weeks: run-in period; 0-24 weeks: active
treatment) for both ADRB2 codon 16 genotype groups (Arg/Arg; Arg/Gly or Gly/Gly). *p values for Arg/Arg compared with Arg/Gly or Gly/Gly at
each time point. FEV1, forced expiratory volume in 1sec; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; ADRB2, β2-adrenergic
receptor.
A B C24 weeks.
There was a significant increase in the quality of life score
during the regularly scheduled combined treatment (Fig. 2B).
After 24 weeks of active treatment, the treatment effects
showed significant differences between the genotype groups;
the Arg/Arg group had a significantly higher quality of life
than the Arg/Gly or Gly/Gly group (p < 0.05), whereas there
was a significant decrease in the symptom score during treat-
ment (Fig. 2A). After 24 weeks of active treatment, the
treatment effects showed significant differences between the 2
genotypes (p < 0.05). However, there was no significant
difference in the requirement for rescue medicine according to
genotype (p > 0.05).
The morning PEFR, measured daily in all subjects, increased
after active treatment (Fig. 3A); the regression equations were y
= 89.59 + 5.99×(1 - 0.97
^ time) for the Arg/Arg genotype and y
= 74.91 + 3.13×(1 - 0.95
^ time) for the Arg/Gly or Gly/Gly
genotypes. The evening PEFR level was also increased after
active treatment, and the equations were y = 90.78 + 6.49×(1 -
0.97^ time) for the Arg/Arg genotype and y = 75.30 + 3.52×(1
- 0.97^ time) for the Arg/Gly or Gly/Gly genotype (Fig. 3B).
The slopes were calculated using the differential equation of the
best-fit line (y = -b×c
^ time×In<c>), the plotted line of each
genotype showed different inclination; the slope for the Arg/
Arg genotype was steeper than that for the Arg/Gly or Gly/Gly
genotype during the active treatment period, however it wasn’t
calculated by a statistical tool. The time to reach the plateau
morning and evening PEFR levels was longer for the Arg/Arg
genotype (87 days for the morning PEFR, 98 days for the
evening PEFR) than for the Arg/Gly or Gly/Gly genotype (52
and 81 days, respectively).
Effect of ADRB2 Polymorphism on Asthma Control
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Fig. 2. Mean (SD) symptom scores (A) and quality of life scores (B) during the active
treatment period for both ADRB2 codon 16 genotype groups (Arg/Arg; Arg/Gly or
Gly/Gly). ADRB2, β2-adrenergic receptor; ACQ, Asthma Control Questionnaire;
AQLQ, Asthma Quality of Life Questionnaire. *p values for Arg/Arg compared with
Arg/Gly or Gly/Gly at each time point.
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Fig. 3.Changes of morning PEF [(A): Arg/Arg genotype group (●), y = 89.59 + 5.99×<1 - 0.97^TIME>; Arg/Gly or Gly/Gly genotype group (○), y = 74.81 + 3.13×< 1 - 0.95^TIME>],
and evening PEF [B: Arg/Arg genotype group (●), y = 90.78 + 6.49×<1 - 0.97^TIME>; Arg/Gly to Gly/Gly genotype group (○), y= 75.30 + 3.52×<1 - 0.97^TIME>] during the study
period, analyzed by non-linear regression and plotted as individual revisable PEFR. �� indicates days to reach the plateau PEFR value in each genotype. PEFR, peak expiratory
flow rate.
A B
A BThe ADRB2 is a G protein-coupled receptor that mediates the
actions of catecholamines in multiple tissues. Nine single-
nucleotide polymorphism (SNPs) have been identified in the
ADRB2 gene,
17 2 of which are more frequent and give rise to
amino acid substitutions in the putative extracellular amino-
terminus region of the gene; Arg for Gly at codon 16 and Gln
for Glu at codon 27. The Gly16 variant has positively been
associated with severe asthma
18,19 and nocturnal asthma.
20 The
bronchodilating response to inhaled short- and long-acting β2-
agonists shows significant inter-individual variation, depending
on the ADRB2 codon 16 genotype,
4-9 although some studies
suggested that the bronchodilating effect caused by rescue
treatment with β2-agonists is influenced by haplotypes of the
ADRB2 gene.
21,22 Furthermore, ethnic differences in the
pharmacogenetic effects of ADRB2 Arg16Gly polymorphism
has been suggested.
15 Choudhry et al.
15 conducted comprehensive
family-based pharmacogenetic study of ADRB2 Arg16Gly
polymorphism and demonstrated that Arg16 allele was
significantly associated with bronchial responsiveness in Puerto
Rican, but not in Mexican, subjects with asthma.
Among two common polymorphisms, Arg16Gly and
Gly27Gln, of ADRB2 gene, only the Arg16Gly polymorphism
was investigated in this study because of very low frequency of
minor allele of the Gly27Gln polymorphism in Korean
9 and
Japanese population.
23 Study subjects having the Arg16Gly
polymorphism were categorized into two groups, such as
Arg/Arg and Arg/Gly plus Gly/Gly groups, because of limited
number for analysis.
Our results suggest that the ADRB2 Arg16Gly genotype
significantly modifies the level of asthma control, as indicated
by improvements in lung function, symptom score, and quality
of life, in patients who underwent initially regular treatment
with a combined ICS (budesonide) and LABA (formoterol).
Our findings suggest that patients with the Arg/Arg genotype
would receive greater benefit from the regular use of the
combined treatment of ICS and LABA as a maintenance
treatment than patients with the Arg/Gly or Gly/Gly genotype.
Our primary outcome variables were FEV1% and MMEF%
predicted values, which are recognized as useful indicators that
correlate well with clinical outcomes in asthma. Along with
these improvements in lung function, patients in the Arg/Arg
group exhibited parallel changes in other outcome variables,
such as the symptom and quality of life scores and morning/
evening PEFR, all suggesting a clinically relevant genotype-
specific effect. Although the Arg/Arg group was younger in
age, asthma duration was not different between the 2 groups
and lung function parameters were presented as % predicted
value, and therefore, the effect of age is likely minimal.  Moreo-
ver, these findings on the difference in the rates of increase of
morning and evening PEFR were replicated, as seen in 2
different genotype-specific equations. Therefore this model
could be applied to predict morning/evening PEFR responses
with long-term regular use of combination treatment.
The pharmacogenetic response to β2-agonist in this study
was not consistent with previous studies in Caucasian subjects
that subjects carrying the Gly/Gly genotype at codon 16 of
ADRB2 achieved a greater bronchodilation response to a short-
acting β2-agonist and a long-acting β2-agonist without ICS,
4-8
however similar to a previous study in a Korean population
9
that individuals carrying the Arg/Arg genotype achieved a
better response to short-acting β2-agonist. This inconsistency
result might be due to pharmaco-ethnic difference: ethenic-
specific pharmacogenetic difference of ADRB2 Arg16Gly was
previously reported between Puerto Rican and Mexican
subjects with asthma.
15 There are several polymorphisms in
ADRB2 gene, and these functional SNPs can change in
receptor expression and signal transduction.
24-27 This means
drug response to inhaled β2-agonists can be altered according
to specific haplotype which is constructed by polymorphisms.
In the present study, however, we focused on the Arg16Gly
because of its important clinical relevance and high minor allele
frequency compared to other polymorphisms. Therefore, we
couldn’t exclude possibility of any pharmacogenetic effect of
other polymorphisms and the pharmaco-ethnic difference
observed might be related to other polymorphisms in linkage
with the ADRB2 Arg16Gly which we studied. 
Different pharmacogenetic effect of ADRB2 polymorphism
on the combination therapy (ICS plus LABA) may be explain-
able by different clinical trial. A recent 6-month double blind
randomized study
14 revealed no genotype effect of ADRB2 on
the combination therapy in 2,250 asthmatics. These investigators
enrolled larger numbers of Arg/Arg homozygous in a longer
treatment period than that of Wechsler et al.
6 The size of the
study population and design of clinical trial are important for
observing pharmacogenetic effect of ADRB2.
In the present study, LABA treatment was combined with
ICS, therefore it is quite possible that the differences in response
to ICS between genotype groups could account for the observed
differences. However, this possibility is quite unlikely, because
that all the study subjects used the same regimen of ICS during
the 2-week run-in, and showed improvement in both FEV1 and
MMEF, with no significant differences observed between
genotype groups. Our preliminary study demonstrated that
genetic variance of ADRB2 at Arg16Gly could not influence
the effect of ICS in a Korean population (unpublished data).
Therefore, we propose that the genotype-specific effects found
in this study may have been derived from the effects of the
long-acting β2-agonist and the ADRB2 Arg16Gly polymor-
phism, although the effects of ICS on the differential response
to LABA according to ADRB2 genotype could not completely
be excluded. 
Another explanation for the difference between this study
and that of Wechsler et al.
6 involves the choice of LABA;
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DISCUSSIONformoterol vs. salmeterol. Cho et al.
9 studied  the response to a
short-acting β2-agonist in a Korean population using albuterol,
and found that those carrying the Arg/Arg genotype had better
responses to albuterol. This result is similar to our present
result, however, dissimilar the finding of long-term albuterol
treatment reported by Israel et al.
4,5 Further investigation is
needed to replicate these observations in other Asian popula-
tions and confirm these apparent pharmaco-ethnic differences.
In this study, FEV1 and MMEF levels in patients with the
Arg/Arg genotype decreased with disappearance of a signifi-
cant difference in the FEV1 level between the 2 genotype
groups at 24 weeks. However, these findings were observed in
subjects with the Arg/Gly or Gly/Gly genotype from 16 weeks.
Moreover, the morning/evening daily PEFR results demonst-
rated that the time to reach the plateau of PEFR levels was
significantly shorter in the Arg/Gly or Gly/Gly genotype,
suggesting that adverse effects such as downregulation of β2-
adrenergic receptor occur earlier in the Arg/Gly or Gly/Gly
type, although the mechanism of this effect remains to be
elucidated. 
In conclusion, Korean asthmatic patients carrying the Arg/
Arg genotype at codon 16 of ADRB2 achieve better asthma
control with long-term use of combined treatment with a long-
acting β2-agonist and ICS, as evidenced by airway function,
asthma symptoms, and quality of life. Because of these effects
and potential pharmaco-ethic differences in response, ADRB2
genotyping is likely to play an increasingly important role in the
choice of treatment for asthmatic patients.
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